Biliary tract cancer (BTC) remains a highly aggressive malignancy with limited treatment options and poor prognosis.
To explore the association between KRAS variants and survival/therapeutic outcomes of patients with BTC, we analyzed genetic and clinical data obtained from BTC patients who underwent comprehensive genomic profiling (CGP) testing in Japan.
